This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q98.2 | Special Copayment Reduction: V218 | Re-certification interval: 5 years |
| B. Synonyms | None |
| C. Adult onset | First manifestation in adulthood common — because men with 46,XX male syndrome look similar to normal men, it is very often first diagnosed in adulthood during evaluation for infertility or hypogonadism. (de la Chapelle syndrome, SRY translocation or SOX9 activation) |
| 1. History | First reported by de la Chapelle in 1964 → named '46,XX male syndrome' in 1966 → SRY gene discovered in 1990 → SRY translocation mechanism established in 1992 → SRY-negative mechanisms (SOX9, SOX10, etc.) elucidated in the 2000s. |
| 2. Causes | About 80%: the SRY gene is translocated to the X chromosome short arm (Xp) by Y-X homologous recombination during meiosis. About 20%: SRY-negative (SOX9 activation, abnormalities of other genes such as SOX3 and RSPO1). |
| 3. Genetics | 46,XX karyotype + SRY translocation (Xp22.3). SRY → SOX9 activation → testis determination. SRY-negative forms: RSPO1 loss of function, SOX9 activating mutations, SOX10 abnormalities. Absence of AZF genes → azoospermia. |
| 4. Epidemiology | About 1 in 20,000~25,000 male births. Accounts for about 0.5~1% of male infertility patients. Occurs sporadically worldwide, including Korea. |
| 5. Pathophysiology | SRY → SOX9 → FGF9 pathway activation → Sertoli cell differentiation → testicular development. Absence of AZF → spermatogenesis impossible. Single copy of SHOX → short stature. |
| 6. Symptoms | Phenotypic male, small testes, azoospermia, hypogonadism (low testosterone), gynecomastia. Short stature (shorter than 47,XXY). Ambiguous external genitalia rare (in the SRY-positive form). |
| 7. Signs | Small testes, elevated FSH, low testosterone, gynecomastia. SRY-negative form: ambiguous external genitalia, possible intellectual disability (varies with accompanying abnormalities). |
| 8. Screening | During evaluation of adult azoospermia and hypogonadism. Small testes and ambiguous external genitalia in childhood. Prenatal: SRY FISH when the 46,XX karyotype and male phenotype are discordant. |
| 9. Diagnosis | Karyotyping (46,XX) + SRY PCR/FISH. If SRY-negative, additional molecular testing for SOX9, RSPO1, etc. Hormone panel, semen analysis. |
| 10. Treatment | Testosterone replacement (lifelong). Corrective surgery for gynecomastia. Infertility: ART not possible (AZF absent). Counseling on sperm donation or adoption. SRY-negative form: DSD-based personalized treatment. |
| 11. Prognosis | Normal life expectancy with appropriate testosterone replacement. Infertility is permanent (TESE not possible). Quality of life depends on hormone treatment and psychological support. |
| 12. Prevention | Genetic counseling. Prenatal diagnosis (SRY analysis when 46,XX is confirmed). Early testosterone replacement. Psychological support related to infertility. |
| 13. References | 10 references (PMID / DOI) |
46,XX male syndrome (de la Chapelle syndrome) began to attract medical attention in 1964 when the Finnish geneticist Albert de la Chapelle first reported a patient with a male phenotype of the external genitalia but a 46,XX karyotype. In 1966, de la Chapelle and colleagues published a systematic clinical description of this syndrome, defining the paradoxical situation of a normal male appearance but a female karyotype (46,XX) under the name 'XX male syndrome'.
Until the 1980s the cause of this syndrome had not been identified, but a turning point came in 1990 when Sinclair et al. and Koopman et al. discovered the SRY (sex-determining region Y) gene located on the short arm of the Y chromosome. In 1991~1992, Berta et al. and de la Chapelle et al. confirmed that in about 80% of 46,XX male patients, part of the sequence of the Y chromosome short arm (including SRY) is translocated to the X chromosome short arm (Xp22.3). This showed that the cause is abnormal recombination between the pseudoautosomal regions (PAR1) of the X and Y chromosomes in paternal meiosis I.
The causes of the remaining approximately 20% of SRY-negative 46,XX males have been gradually revealed by molecular genetic research since the 2000s. It has been shown that SOX9 amplification (copy number variants or enhancer mutations), SOX10 abnormalities, RSPO1 loss-of-function mutations, etc. can induce testicular development even without SRY. In particular, biallelic RSPO1 loss-of-function mutations are recognized as constituting a separate syndrome that causes virilization and skin abnormalities (hypertonic skin, palmoplantar keratosis, increased risk of squamous cell carcinoma) in 46,XX individuals.
It is currently coded as Q98.2 in the ICD-10 classification and is classified as a variant of Klinefelter syndrome, but because it is actually an abnormality of the sex determination mechanism, it is also discussed in the DSD (disorders of sex development) category. With advances in molecular diagnosis, confirmation of SRY translocation and identification of the genetic causes of the SRY-negative form are becoming increasingly precise.
46,XX male syndrome (Q98.2) is divided into two main etiological mechanisms.
During paternal meiosis I, obligatory recombination occurs in pseudoautosomal region 1 (PAR1) of the X and Y chromosomes; if this recombination occurs abnormally at the boundary between PAR1 and the Y chromosome short arm (proximal to the PAR1-Y boundary), the terminal Y short arm sequence containing the SRY gene is translocated to the X chromosome short arm (Xp22.3). As a result, a single sperm contains both an X chromosome and the SRY sequence, and when this sperm fertilizes an X egg, a 46,XX + SRY individual is born. As the testis-determining factor, the SRY gene activates SOX9 expression, inducing Sertoli cell differentiation and leading to testicular development. In this process, the rest of the Y chromosome (including the AZF region) is not transmitted, so spermatogenesis genes (AZFa, AZFb, AZFc) are lacking, which is the direct cause of azoospermia.
The mechanisms by which 46,XX males arise without SRY translocation are diverse. SOX9 amplification: increased copy number (duplication) of the SOX9 gene or mutations in SOX9 enhancers (TESCO, ERCE1/2, etc.) cause high SOX9 expression even without SRY, inducing testicular development. RSPO1 loss of function: RSPO1 enhances Wnt/β-catenin signaling to promote ovarian development and suppress testicular development, and 46,XX virilization occurs with heterozygous or homozygous loss-of-function mutations of this gene. SOX10: cases in which SOX10 abnormalities were associated with SRY-negative 46,XX males have recently been reported. In the SRY-negative form, additional features such as ambiguous external genitalia, intellectual disability and skin abnormalities (RSPO1 type) may accompany it more than in the SRY-positive form.
The key genetic features of SRY translocation-type 46,XX males are as follows. The karyotype is 46,XX, but Y chromosome-derived sequence (including SRY) is inserted at the terminal end of the X chromosome short arm (Xp22.3). In addition to SRY, this translocated sequence may include adjacent Y sequences (AMELY, part of ZFY, etc.).
The main clinical consequences of this genotype arise from the following. First, absence of AZF genes: because the AZFa, AZFb and AZFc regions located on the Y long arm and proximal to the long-short arm junction are not transmitted, essential spermatogenesis genes such as USP9Y, DBY, RBMY and DAZ are absent, making spermatogenesis fundamentally impossible. Second, single copy of SHOX: whereas in 47,XXY there are three SHOX copies (XXY, i.e., two copies in PAR1 plus one copy in Y PAR1), in 46,XX males there are two (XX PAR1 + two if the translocated Xp terminal sequence does not contain SHOX, three if it does). Therefore they tend to be shorter than 47,XXY. Third, one X chromosome is inactivated, but PAR1 and the translocated SRY sequence are not inactivated.
In the SRY-negative form, SOX9 enhancer mutations show sporadic or familial occurrence patterns, and RSPO1 loss of function shows an autosomal recessive inheritance pattern. In molecular diagnosis, if SRY PCR is negative, panel testing for SOX9, RSPO1, SOX10, etc. or whole-genome analysis is useful.
46,XX male syndrome is a rare disease occurring at a frequency of about 1 per 20,000~25,000 male births. About 2,000~3,000 patients are estimated to have been reported worldwide, but many cases are presumed to go undiagnosed because symptoms are mild.
Among patients presenting to male infertility clinics with azoospermia, about 0.5~1% are identified as 46,XX males. This disease is most often first found in adulthood during evaluation for infertility or hypogonadism. Some cases are diagnosed in childhood due to small testes, ambiguous external genitalia or delayed puberty. In the SRY-negative form (~20%), diagnosis in the neonatal period due to ambiguous external genitalia is more common.
Differences in incidence by region and race are not clear. Recurrence is almost nonexistent, and recurrence in the children of parents with this disease is extremely rare. Because SRY translocation arises from a paternal meiotic error, the frequency of paternal X-Y recombination may be regarded as a risk factor, but there is currently no way to predict it. In Korea it is registered under rare disease Special Copayment Reduction V218 (Q98 group).
The pathophysiology of SRY translocation-type 46,XX males is understood along two axes: testis determination by the SRY gene and azoospermia due to the absence of AZF genes.
SRY is a single-exon gene located in the sex-determining region of the Y chromosome short arm and functions as the testis-determining factor (TDF). SRY is expressed in gonadal supporting cell precursors and directly activates SOX9. SOX9 induces Sertoli cell differentiation, promotes the testicular development pathway through signals such as FGF9 and PGD2, and suppresses the ovarian development pathway (WNT4/RSPO1/β-catenin). As a result, testes form; anti-Müllerian hormone (AMH) is secreted from Sertoli cells, causing regression of Müllerian structures (uterus, fallopian tubes), and testosterone is secreted from Leydig cells, causing development of structures derived from the Wolffian duct (epididymis, vas deferens, seminal vesicles). As a result, the external genitalia differentiate into the male phenotype under the influence of DHT.
However, because spermatogenesis genes such as DAZ, RBMY, USP9Y and DBY in the AZF region (azoospermia factor region) located on the long arm and proximal short arm of the Y chromosome are not included in the translocated sequence, spermatogenesis is completely blocked. After puberty, testicular tissue shows a Sertoli cell-only syndrome pattern in which no spermatogenic cells develop at all.
SHOX haploinsufficiency: in 46,XX males, if the translocated sequence does not contain the SHOX gene, SHOX is expressed only from the PAR1 of the two X chromosomes (one inactivated), and having fewer copies than normal males (XY, PAR1+PAR1) results in short stature. This is an important clinical difference in contrast to the tall stature due to three SHOX copies in 47,XXY.
In the SRY-negative form, SOX9 overexpression or RSPO1 deficiency causes the same outcome (testicular development), but intellectual disability, skin abnormalities, ambiguous external genitalia, etc. may additionally occur due to accompanying gene abnormalities.
SRY-positive 46,XX males (about 80% of the total) have an external phenotype very similar to normal males, making clinical suspicion difficult.
Infertility (azoospermia) is the most common symptom, mostly discovered during infertility evaluation in adulthood. Small testes can be found on physical examination but are often overlooked as they are not conspicuous. Hypogonadism (low testosterone, elevated FSH/LH) causes symptoms such as low energy, decreased libido, erectile dysfunction and hot flushes. Gynecomastia occurs in about 30~60%. Short stature is more pronounced than in 47,XXY (2 copies of SHOX), with mean height tending to be about 5~7 cm lower than in normal men. Intelligence is normal, and there is no language developmental delay. Puberty begins spontaneously but may progress incompletely.
Ambiguous external genitalia (varying from partial virilization to a near-female phenotype) appear, so diagnosis is often made in the neonatal period. In the RSPO1 loss-of-function form, palmoplantar keratoderma, increased risk of squamous cell carcinoma and 46,XX ovotesticular DSD may accompany it. Intellectual disability is reported in some.
The main signs identified on physical examination and testing are described.
Small testes (adult volume 2~8 mL by Prader orchidometer, similar to or somewhat smaller than 47,XXY). In the SRY-positive form, the external genitalia have a normal male form. In the SRY-negative form, clitoromegaly, labial fusion, hypospadias and abnormal gonadal position within the scrotum are possible.
Markedly elevated FSH (several times the upper limit of normal or more), elevated LH, low or low-normal serum total testosterone, undetectable or very low inhibin B, very low AMH. This reflects the presence of Sertoli cells but absence of spermatogenic cells in the testes.
Complete azoospermia. No sperm found even on testicular sperm extraction (TESE) (Sertoli cell-only syndrome findings). This is entirely different from the possibility of TESE success in 47,XXY; in 46,XX males, the AZF genes themselves are absent, so obtaining sperm is fundamentally impossible.
Decreased bone density on DEXA. Abnormal bone metabolism due to estrogen/testosterone imbalance and testosterone deficiency.
Palmoplantar keratoderma (hyperkeratosis), degenerative skin lesions. Dermatological monitoring is needed for early detection of squamous cell carcinoma.
Diagnosis of 46,XX male syndrome begins with clinical suspicion.
In male infertility patients presenting with azoospermia, karyotyping is the standard test. It should also be suspected with the combination of elevated FSH, low testosterone and small testes. When the karyotype is confirmed as 46,XX, SRY PCR/FISH is performed immediately.
Ambiguous external genitalia in the neonatal period (especially when a 46,XX karyotype or SRY negativity is suspected). Delayed puberty and small testes. Incomplete virilization of unknown cause. In all of these situations, karyotyping + SRY analysis is recommended.
If cfDNA reports a 46,XX karyotype but male external genitalia are seen on ultrasound, immediate invasive confirmation (karyotype + SRY PCR after amniocentesis) is needed. Conversely, if cfDNA reports 46,XY but a female phenotype is seen on ultrasound, SRY dysfunction, complete androgen insensitivity syndrome, etc. must be excluded.
Confirmation is made in two steps.
Step 1: peripheral blood karyotyping confirms 46,XX. At this point, SRY PCR (amplification of SRY-specific sequence from blood or buccal mucosal DNA) is performed immediately.
Step 2: SRY analysis. If SRY PCR is positive, FISH confirms the SRY signal on the X chromosome short arm (Xp22.3). Array CGH or SNP array precisely analyzes the size of the translocated region and the range of included genes (whether SRY and SHOX are included). If SRY PCR is negative, a sex-determination gene panel including SOX9 (17q24.3) copy number variants, SOX9 enhancer variants, RSPO1 (1p34.3) point mutations and SOX10 (22q13.1) analysis, or whole-exome/genome analysis, is performed.
Functional assessment: hormone panel (FSH, LH, testosterone, inhibin B, AMH), semen analysis, testicular ultrasound (size, echo pattern), bone density (DEXA), psychological assessment (if needed). In the SRY-negative form, dermatological examination (possible RSPO1 type) and neurodevelopmental assessment (intellectual disability accompanies some cases).
Treatment of 46,XX male syndrome centers on management of hypogonadism, presentation of realistic alternatives for infertility, and psychological support.
When pubertal progression is incomplete or hypogonadism is confirmed in adulthood, testosterone replacement therapy is started. The goal is to maintain normal male serum testosterone levels, and formulations such as intramuscular injection, transdermal gel and patches are chosen according to patient preference. Testosterone replacement improves muscle mass, bone density, sexual function, energy level and mood. Adverse effects such as erythrocytosis and prostatic hypertrophy are monitored regularly.
In 46,XX males, because the AZF genes are absent, sperm retrieval is impossible by any method, including TESE. This clearly differs from 47,XXY, in which sperm can sometimes be obtained by TESE+ICSI, so this difference must be clearly explained at diagnosis. Because biological fatherhood is not possible, counseling on sperm donation (donor sperm + IUI or IVF) or adoption is needed.
Gynecomastia causing psychological distress is treated with surgical correction (excision of glandular tissue).
In the RSPO1 loss-of-function form, regular dermatological follow-up (early detection of squamous cell carcinoma) is essential. When ambiguous external genitalia are present, whether to perform surgical reconstruction is decided in cooperation with a DSD multidisciplinary team. When intellectual disability is present, neurodevelopmental support and special education are provided.
The life expectancy of SRY-positive 46,XX males is close to normal with appropriate testosterone replacement therapy. An increased risk of cardiovascular disease, diabetes and metabolic syndrome similar to 47,XXY has been reported, so regular metabolic monitoring is needed.
Infertility is permanent, and having biological children using one's own sperm is impossible by any method, including TESE. Because this is a serious psychological shock for many patients, sufficient psychological counseling and support are needed from the time of diagnosis. It has been reported that the quality of life of patients who experience the joy of parenting through sperm donation or adoption improves significantly.
Cognitive and social function are normal in the SRY-positive form, and academic and occupational achievement are similar to the general population. In the SRY-negative form, prognosis varies due to intellectual disability, skin disease and additional malformations depending on the accompanying gene abnormalities. Breast cancer risk depends on whether gynecomastia persists and decreases after surgical correction.
Primary prevention of 46,XX male syndrome is difficult due to the sporadic nature of meiotic recombination errors. However, quality of life can be improved through prevention of complications and psychological support.
Children of 46,XX male patients are possible only through sperm donation, so there is no recurrence risk. However, when autosomal recessive inheritance (RSPO1 type, etc.) is confirmed in the SRY-negative form, siblings are at risk, and family genetic counseling is needed. When the sex chromosomes on prenatal cfDNA and the ultrasound phenotype are discordant, confirmation is made by amniocentesis + SRY analysis.
Testosterone replacement is started from early puberty to achieve normal virilization, maintain bone density and prevent metabolic complications. In adulthood as well, regular level measurement and appropriate replacement are maintained.
From the time of diagnosis, support for accepting infertility, alternative parenthood planning (sperm donation, adoption) and maintaining relationships is provided through referral to mental health professionals. In the RSPO1 type, squamous cell carcinoma is detected early through regular dermatological follow-up for preventive management.